AMRX — Amneal Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $2.34bn
- $4.84bn
- $2.79bn
- 66
- 86
- 68
- 86
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.39 | ||
| PEG Ratio (f) | 0.12 | ||
| EPS Growth (f) | 612.08% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 10.65 | ||
| Price to Sales | 0.84 | ||
| EV to EBITDA | 9.88 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.51% | ||
| Return on Equity | n/a | ||
| Operating Margin | 8.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,992.52 | 2,093.67 | 2,212.3 | 2,393.61 | 2,793.96 | 3,026.94 | 3,238.66 | 11.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +209.81 | +19.69 | n/a | n/a | n/a | +17.13 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Directors
- Paul Meister NEC (68)
- Chirag Patel PRE (54)
- Chintu Patel CCE (49)
- Anastasios Konidaris CFO (54)
- Nikita Shah CHO (43)
- Andrew Boyer EVP (55)
- Joseph Todisco EVP (45)
- Stephen Manzano SVP (56)
- Emily Alva DRC (46)
- Gautam Patel DRC (48)
- J. Kevin Buchi IND (66)
- Jeffrey George IND (47)
- John Kiely IND (62)
- Ted Nark IND (62)
- Shlomo Yanai IND (68)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 23rd, 2023
- Public Since
- November 18th, 2009
- No. of Shareholders
- 154
- No. of Employees
- 8,100
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 313,382,260
- Address
- 400 Crossing Boulevard, 3rd Floor, BRIDGEWATER, 08807
- Web
- https://amneal.com/
- Phone
- Contact
- Anthony Dimeo
- Auditors
- Ernst & Young LLP
Upcoming Events for AMRX
Q1 2025 Amneal Pharmaceuticals Inc Earnings Release
Amneal Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Amneal Pharmaceuticals Inc Earnings Release
Similar to AMRX
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
Arcutis Biotherapeutics
NASDAQ Global Select Market
FAQ
What is the Amneal Pharmaceuticals share price?
As of Today at 19:13 UTC, shares in Amneal Pharmaceuticals are trading at $7.48. This share price information is delayed by 15 minutes.
How has the Amneal Pharmaceuticals share price performed this year?
Shares in Amneal Pharmaceuticals last closed at $7.48 and the price had moved by +26.78% over the past 365 days. In terms of relative price strength the Amneal Pharmaceuticals share price has outperformed the S&P500 Index by +17.02% over the past year.
What are the analyst and broker recommendations for Amneal Pharmaceuticals?
The overall consensus recommendation for Amneal Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Amneal Pharmaceuticals dividend yield?
Amneal Pharmaceuticals does not currently pay a dividend.
Does Amneal Pharmaceuticals pay a dividend?
Amneal Pharmaceuticals does not currently pay a dividend.
When does Amneal Pharmaceuticals next pay dividends?
Amneal Pharmaceuticals does not currently pay a dividend.
How do I buy Amneal Pharmaceuticals shares?
To buy shares in Amneal Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Amneal Pharmaceuticals?
As of the previous close price of $7.48, shares in Amneal Pharmaceuticals had a market capitalisation of $2.34bn.
Where are Amneal Pharmaceuticals shares listed?
Here are the trading details for Amneal Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AMRX
What kind of share is Amneal Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Amneal Pharmaceuticals is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Amneal Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Amneal Pharmaceuticals is $10.00. That is 33.69% above the last closing price of $7.48.
Analysts covering Amneal Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $0.68 for the next financial year.
Find out moreWhat is the trend in the Amneal Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amneal Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -6.14%.
As of the last closing price of $7.48, shares in Amneal Pharmaceuticals were trading -8.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Amneal Pharmaceuticals PE Ratio?
The Amneal Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 10.39. The shares last closed at $7.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Amneal Pharmaceuticals?
Amneal Pharmaceuticals' management team is headed by:
- Paul Meister - NEC
- Chirag Patel - PRE
- Chintu Patel - CCE
- Anastasios Konidaris - CFO
- Nikita Shah - CHO
- Andrew Boyer - EVP
- Joseph Todisco - EVP
- Stephen Manzano - SVP
- Emily Alva - DRC
- Gautam Patel - DRC
- J. Kevin Buchi - IND
- Jeffrey George - IND
- John Kiely - IND
- Ted Nark - IND
- Shlomo Yanai - IND